Effects of D₃K₂ With Periodontal Therapy in Diabetes Mellitus and Stage I-II Periodontitis Patients.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE Oral diseases Pub Date : 2024-10-06 DOI:10.1111/odi.15147

Tolga Aydogan, Meltem Karsiyaka Hendek, Berrin Unsal, Aydın Çifci, Hakan Varol, Uçler Kisa, Ebru Olgun

{"title":"Effects of D3K2 With Periodontal Therapy in Diabetes Mellitus and Stage I-II Periodontitis Patients.","authors":"Tolga Aydogan, Meltem Karsiyaka Hendek, Berrin Unsal, Aydın Çifci, Hakan Varol, Uçler Kisa, Ebru Olgun","doi":"10.1111/odi.15147","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study is to look into the clinical and biochemical outcomes of D3K2 supplementation in addition to nonsurgical periodontal treatment (NSPT) for patients suffering from diabetes mellitus (DM) and periodontitis.Methods: Thirty-eight participants with DM and periodontitis were randomized into two different groups. The test group provided NSPT with D3K2 whereas the control group received NSPT with placebo. Clinical periodontal parameters were recorded and serum and gingival crevicular fluid (GCF) were sampled at baseline and at the third and the sixth months after treatment. Glycated hemoglobin A1c (HbA1c), fasting blood glucose (FBG), 25(OH)D3, parathyroid hormone (PTH), calcium (Ca) and magnesium (Mg) values were determined in blood samples. GCF and serum interleukin (IL)-1β and IL-10 levels were analyzed using enzyme-linked immunosorbent assay.Results: All clinical periodontal parameters were importantly decreased at the third and sixth months after treatment compared to baseline in both groups. At the sixth month, 25(OH)D3 levels in the test group were observed to be statistically significantly higher than in the control group (p = 0.02). Serum IL-1β showed a statistically significant decrease at the sixth month compared to baseline and the third month in control group.Conclusion: According to this study, there is limited additional benefit of D3K2 given with NSPT in individuals with DM and periodontitis.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.15147","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study is to look into the clinical and biochemical outcomes of D₃K₂ supplementation in addition to nonsurgical periodontal treatment (NSPT) for patients suffering from diabetes mellitus (DM) and periodontitis.

Methods: Thirty-eight participants with DM and periodontitis were randomized into two different groups. The test group provided NSPT with D₃K₂ whereas the control group received NSPT with placebo. Clinical periodontal parameters were recorded and serum and gingival crevicular fluid (GCF) were sampled at baseline and at the third and the sixth months after treatment. Glycated hemoglobin A1c (HbA1c), fasting blood glucose (FBG), 25(OH)D₃, parathyroid hormone (PTH), calcium (Ca) and magnesium (Mg) values were determined in blood samples. GCF and serum interleukin (IL)-1β and IL-10 levels were analyzed using enzyme-linked immunosorbent assay.

Results: All clinical periodontal parameters were importantly decreased at the third and sixth months after treatment compared to baseline in both groups. At the sixth month, 25(OH)D₃ levels in the test group were observed to be statistically significantly higher than in the control group (p = 0.02). Serum IL-1β showed a statistically significant decrease at the sixth month compared to baseline and the third month in control group.

Conclusion: According to this study, there is limited additional benefit of D₃K₂ given with NSPT in individuals with DM and periodontitis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

D3K2 对糖尿病和 I-II 期牙周炎患者牙周治疗的影响

研究背景本研究旨在探讨糖尿病（DM）和牙周炎患者在接受非手术牙周治疗（NSPT）的同时补充 D3K2 的临床和生化效果：38名糖尿病和牙周炎患者被随机分为两组。试验组接受含 D3K2 的 NSPT 治疗，对照组接受含安慰剂的 NSPT 治疗。记录临床牙周参数，并在基线、治疗后的第三和第六个月采集血清和牙龈缝隙液（GCF）样本。测定血样中的糖化血红蛋白 A1c (HbA1c)、空腹血糖 (FBG)、25(OH)D3、甲状旁腺激素 (PTH)、钙 (Ca) 和镁 (Mg) 值。使用酶联免疫吸附试验分析了GCF和血清白细胞介素（IL）-1β和IL-10的水平：结果：治疗后第三和第六个月，两组患者的所有临床牙周参数与基线相比均显著下降。第 6 个月时，试验组的 25(OH)D3 水平明显高于对照组，差异有统计学意义（P = 0.02）。与对照组的基线和第三个月相比，血清 IL-1β 在第六个月出现了统计学意义上的显著下降：根据这项研究，D3K2与NSPT一起服用对糖尿病和牙周炎患者的额外益处有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.